Cantor Fitzgerald Reiterates Neutral Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report)‘s stock had its “neutral” rating restated by Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $165.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential downside of 1.30% from the stock’s previous close.

ALNY has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, December 15th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, November 14th. Wells Fargo & Company initiated coverage on shares of Alnylam Pharmaceuticals in a report on Friday, December 8th. They issued an “equal weight” rating and a $171.00 price target on the stock. Finally, Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $175.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $230.95.

Read Our Latest Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded down $2.86 during trading hours on Monday, hitting $167.17. The company’s stock had a trading volume of 299,144 shares, compared to its average volume of 642,855. The company has a market cap of $20.98 billion, a price-to-earnings ratio of -40.46 and a beta of 0.43. The business has a 50 day simple moving average of $183.74 and a two-hundred day simple moving average of $179.49. Alnylam Pharmaceuticals has a 52-week low of $148.10 and a 52-week high of $227.91.

Insider Activity

In other news, Director Michael W. Bonney sold 30,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total transaction of $5,850,000.00. Following the completion of the transaction, the director now directly owns 16,029 shares in the company, valued at $3,125,655. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.40% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Norges Bank bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $390,438,000. Capital International Investors grew its position in Alnylam Pharmaceuticals by 29.2% in the 2nd quarter. Capital International Investors now owns 2,880,643 shares of the biopharmaceutical company’s stock worth $547,152,000 after purchasing an additional 651,054 shares during the period. Wellington Management Group LLP grew its position in Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after purchasing an additional 364,021 shares during the period. Eaton Vance Management grew its position in shares of Alnylam Pharmaceuticals by 606.7% during the 1st quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after acquiring an additional 262,893 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Alnylam Pharmaceuticals by 39.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 775,596 shares of the biopharmaceutical company’s stock valued at $147,317,000 after acquiring an additional 221,259 shares during the period. Institutional investors own 93.98% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Stories

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.